Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor
AssigneeMaison Amori oqvpo LLC
InventorNicola J. NASSER
Life of this patent
Estimating the term…
Abstract
Methods, compositions, uses and kits can be provided to treat cancer in a subject, which can include administering to the subject an active agent to induce enhanced tumor cell mitosis, and providing, in proximity or immediately after that, a therapy that specifically targets cells in mitosis, such as chemotherapy or radiation.
Claims22
A method for treating cancer in a subject, comprising:
- (a) administering to the subject a medication in an amount effective to specifically induces mitosis of cancer cells, and
- (b) applying a treatment that kills cells in mitosis 8-150 hours, 12-150 hours, or 8-120 hours after step (a).
A kit comprising:
- a self-injectable prefilled needle, comprising a prefilled syringe that is permanent or disposable, that includes an active agent comprising LHRH, an LHRH agonist, a decapeptide (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2;
- SEQ ID NO:1), Gonadorelin, leuprolide, a modification thereof, or a combination thereof, and
- an instruction for administering to a subject the active agent 8-150 hours before starting chemotherapy.
A method for treating a hormone sensitive malignancy in a subject, the method comprising:
- administering to the subject at least one of:
- a) an immediate release LHRH agonist or testosterone for treating prostate cancer 8-48 hours before a start of a radiation week so a radiation is delivered when tumor cells are dividing;
- or
- b) progesterone for treating breast cancer 8-48 hours before the start of the radiation week, so that the radiation is delivered when the tumor cells are dividing.
A method for treating hormone receptor positive breast cancer, in a premenopausal subject, comprising:
- providing a mitosis-targeting chemotherapy at least one of:
- a) when at least one of (i) an ovary of the subject is in a follicular phase of a menstrual cycle or (ii) estradiol approaches peak levels for estrogen receptor positive cancer;
- or
- b) for at least one of estrogen receptor negative, progesterone receptor positive, breast cancer during a luteal phase of an ovarian cycle of the subject, or when progesterone reaches a peak level.
A method comprising delivering a therapeutic agent targeting the pituitary gland, alone or together with a pharmaceutically acceptable carrier through an intranasal device, wherein the therapeutic agent includes at least one of Gonadorelin, leuprolide, a Luteinizing Hormone-Releasing Hormone analogue, a Corticotropin-releasing hormone, a thyrotropin-releasing hormone, or a Growth hormone-releasing hormone.
Dependencies are inferred from the claim text.